Aison Technologies obtains CE-Mark and opens production facility in Poland

Aison Technologies (formerly Caressoma) aims to make sonography easier by designing tools that accelerate ultrasound procedures and make both interventions and diagnostics more accurate. Because existing ultrasound probes are stiff, it is difficult to precisely scan uneven body surfaces, which may lead to misdiagnoses. Often, pressure must be applied to obtain a better view, which causes discomfort, or even pain to injured patients.

The start-up’s most advanced device, the aiSon FOCUS, addresses this challenge – as the world’s only adaptive ultrasound standoff pad, which continuously adapts its shape to that of the scanned anatomy. Attached to any existing ultrasound probe, the liquid-filled pad allows practitioners to scan uneven areas of the body effortlessly and obtain higher-quality images.

During its recent stages of development, the start-up shipped over 500 units to early adopters in a wide range of fields, including dermatology, anesthesiology, radiology, emergency care, and paediatrics, enabling it to collect feedback, support research and development (R&D), and generate revenues. With the receipt of the CE-mark, Aison enters the official commercialisation phase with a certified medical device.

In addition to the CE certification, the start-up has set up a production facility in Poland to serve a broad range of customers across Europe. Under the leadership of co-founder Jinesh Kallunkathariyil and a new team, the subsidiary will have the capacity to produce up to 7000 units per month, a sevenfold increase. Aison’s Swiss headquarters will double down on R&D, continuing to create cutting-edge ultrasound-enhancing technology, as well as leading its commercial efforts.

Seed round completed
In addition to early revenues, Aison received a seed-financing round supported by business angels to accelerate development and build the larger production facility. For the next growth phase, Aison now seeks fresh capital to grow the team and support marketing and distribution activities.

“The CE-mark proves our strong commitment to providing high-quality ultrasound solutions that benefit both patients and healthcare professionals,” remarks the start-up’s CEO and co-founder, Dr Sophia Borowka. “While we enter the market with the aiSon FOCUS, we are advancing the development of our two additional devices. The aiSon 3D, designed to focus on rheumatoid arthritis diagnostics, is scheduled to launch in 2023. Together with the aiSon STANDARDIZE, it aims to offer standardised ultrasound images, allowing for consistent patient follow-ups, higher-quality diagnoses and the ability to see more patients in less time,” she adds.

(RAN)